Aulos Bioscience, an immuno-oncology company focused on advancing cancer care through innovative IL-2 therapeutics, has announced the presentation of encouraging safety and efficacy data from the Phase 2 dose expansion cohorts of its Phase 1/2 clinical trial for AU-007. This trial targets patients with unresectable locally advanced or metastatic solid tumors. The findings will be shared at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, taking place virtually and in Houston, Texas, from November 6-10, 2024.
“The Phase 2 dose expansion data for our monoclonal antibody, AU-007, continue to build on the positive results we presented at ASCO. We look forward to providing more details, especially regarding early Phase 2 results in melanoma and renal cell carcinoma, at the SITC Annual Meeting,” said Aron Knickerbocker, President and CEO of Aulos Bioscience.
Details of the Poster Presentation:
- Title: A Phase 1/2 Dose Escalation and Cohort Expansion Study of AU-007, a Human Monoclonal Antibody (mAb) that Binds to IL-2 and Inhibits CD25 Binding, Plus Low-Dose Aldesleukin in Advanced Solid Tumors
- Abstract: 685
- Date and Time: Friday, November 8, 2024, 9:00 a.m.-7:00 p.m. CST
- Location: Exhibit Halls AB at the George R. Brown Convention Center. An electronic version will also be available on the SITC 2024 virtual meeting platform.
About AU-007
AU-007 is a computationally designed human IgG1 monoclonal antibody that selectively targets the CD25-binding region of IL-2. Its unique mechanism enhances anti-tumor immune responses by preventing IL-2 from binding to regulatory T cells, while still allowing its binding to effector T cells and NK cells. This helps avoid the negative feedback associated with other IL-2 therapies and promotes immune activation. Additionally, AU-007 reduces IL-2 binding to CD25 receptors on eosinophils and vascular tissues, potentially mitigating the vascular leak syndrome and pulmonary edema seen with high-dose IL-2 therapy.
For more information about the AU-007 Phase 1/2 clinical trial program, including study locations in the U.S. and Australia, visit ClinicalTrials.gov (identifier: NCT05267626) or the respective study websites for the U.S. and Australia.
About Aulos
Aulos Bioscience aims to transform cancer patient care through cutting-edge IL-2 therapeutics that mobilize the immune system to attack tumor cells. Combining advanced machine learning from co-founder Biolojic Design with deep expertise in immunology, Aulos’ initial candidate, AU-007, is designed to harness IL-2’s tumor-killing potential while minimizing the immunosuppression and side effects typically associated with this pathway. Founded by Biolojic Design and Apple Tree Partners, Aulos is led by pioneers in artificial intelligence, antibody development, and cancer immunotherapy.
